<DOC>
	<DOCNO>NCT01839097</DOCNO>
	<brief_summary>The primary objective study determine Maximum Tolerated Dose ( MTD ) belinostat combine CHOP regimen establish recommend belinostat dose Phase 3 study .</brief_summary>
	<brief_title>Phase 1 Dose Finding Study Belinostat Treatment Patients With Peripheral T-cell Lymphoma ( PTCL )</brief_title>
	<detailed_description>This Phase 1 dose find study use traditional escalation rule 3+3 design evaluate Maximum Tolerated Dose ( MTD ) belinostat administer combination CHOP .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Age 18 year Life Expectancy &gt; 3 month Histologically confirm diagnosis PTCL Patients transform CTCL eligible CHOP regimen Measurable disease base Cheson 2007 criterion Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 Known active Hepatitis B/ Hepatitis C/ HIV infection Known , uncontrolled CNS metastasis primary CNS lymphoma Deep vein thrombosis diagnose within 3 month Ongoing treatment preexist cardiovascular disease Neuropathy Grade 3 Previous extensive radiotherapy except limited field RT locally advance nasal NK PTCL pain palliation Prior therapy severely myelotoxic regimen , include autologous allogenic stem cell transplantation Prior therapy HDAC inhibitor ( except CTCL ) Inadequate hematological , hepatic , renal function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>PTCL</keyword>
	<keyword>Maximum Tolerated Dose</keyword>
	<keyword>Belinostat</keyword>
</DOC>